Recombinant erythropoietin long-acting - Shandong Kexing Bioproducts
Latest Information Update: 07 Feb 2014
At a glance
- Originator Shandong Kexing Bioproducts Co; Unknown
- Developer Shandong Kexing Bioproducts Co
- Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Anaemia
Most Recent Events
- 01 Jan 2014 Investigation in Anaemia in China (Parenteral)